| dc.contributor.author | Runfeng, L, et al. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong | |
| dc.date.accessioned | 2020-03-25T12:41:35Z | |
| dc.date.available | 2020-03-25T12:41:35Z | |
| dc.date.issued | 2020-03-20 | |
| dc.identifier.uri | https://doi.org/10.1016/j.phrs.2020.104761 | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/804 | |
| dc.description.abstract | Purpose: Lianhuaqingwen (LH) as traditional Chinese medicine (TCM) formula has been used to treat influenza and exerted broad-spectrum antiviral effects on a series of influenza viruses and immune regulatory effects [1]. The goal of this study is to demonstrate the antiviral activity of LH against the novel SARS-CoV-2 virus and its potential effect in regulating host immune response.
Methods: The antiviral activity of LH against SARS-CoV-2 was assessed in Vero E6 cells using CPE and plaque reduction assay. The effect of LH on virion morphology was visualized under transmission electron microscope. Pro-inflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays.
Results: LH significantly inhibited SARS-CoV-2 replication in Vero E6 cells and markedly reduced pro-inflammatory cytokines (TNF-α, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Furthermore, LH treatment resulted in abnormal particle morphology of virion in cells.
Conclusions: LH significantly inhibits the SARS-COV-2 replication, affects virus morphology and exerts anti-inflammatory activity in vitro. These findings indicate that LH protects against the virus attack, making its use a novel strategy for controlling the COVID-19 disease. | en_US |
| dc.language | English | en_US |
| dc.subject | Lianhuaqingwen | en_US |
| dc.subject | Anti-inflammatory | |
| dc.subject | Coronavirus | |
| dc.subject | COVID-19 | |
| dc.subject | SARS-CoV | |
| dc.title | Lianhuaqingwen Exerts Anti-Viral and Anti-Inflammatory Activity Against Novel Coronavirus (SARS-CoV-2) | en_US |
| eihealth.country | China | en_US |
| eihealth.category | Candidate therapeutics RD | en_US |
| eihealth.type | Published Article | en_US |
| eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
| dc.relation.ispartofjournal | Pharmacol Res. | en_US |
